tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TAK Stock Latest News

Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy
Company AnnouncementsTakeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy
2d ago
TAK
Takeda Pushes Pediatric Psoriasis Drug TAK-279 Forward With New Phase 3 Trial Update
PremiumCompany Announcements
Takeda Pushes Pediatric Psoriasis Drug TAK-279 Forward With New Phase 3 Trial Update
2d ago
TAK
Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial
PremiumCompany Announcements
Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial
4d ago
TAK
Takeda granted Priority Review for oveporexton by FDA
PremiumThe Fly
Takeda granted Priority Review for oveporexton by FDA
5d ago
TAK
Takeda’s Elritercept Study Signals Long-Term Bet on MDS Anemia Innovation
PremiumCompany Announcements
Takeda’s Elritercept Study Signals Long-Term Bet on MDS Anemia Innovation
9d ago
TAK
Takeda’s Fazirsiran Phase 3 Liver Study Progresses, Strengthening Its Rare-Disease Pipeline Story
PremiumCompany AnnouncementsTakeda’s Fazirsiran Phase 3 Liver Study Progresses, Strengthening Its Rare-Disease Pipeline Story
9d ago
TAK
Takeda’s TAK-188 Trial: Early Immunotherapy Bet in Advanced Solid Tumors
Premium
Company Announcements
Takeda’s TAK-188 Trial: Early Immunotherapy Bet in Advanced Solid Tumors
9d ago
TAK
Takeda Advances TAK-360 Sleep Disorder Trial, Signaling Growing Ambition in Orexin-Based Therapies
Premium
Company Announcements
Takeda Advances TAK-360 Sleep Disorder Trial, Signaling Growing Ambition in Orexin-Based Therapies
9d ago
TAK
Takeda Advances Orexin-Mimicking Narcolepsy Drug TAK-360 Into Active Mid-Stage Testing
PremiumCompany Announcements
Takeda Advances Orexin-Mimicking Narcolepsy Drug TAK-360 Into Active Mid-Stage Testing
9d ago
TAK
Takeda Advances Elritercept Study in Myelofibrosis, Keeping Anemia-Focused Pipeline in the Spotlight
PremiumCompany Announcements
Takeda Advances Elritercept Study in Myelofibrosis, Keeping Anemia-Focused Pipeline in the Spotlight
10d ago
TAK
Takeda’s Mezagitamab ITP Extension Study: Long-Term Data That Matters for Investors
PremiumCompany Announcements
Takeda’s Mezagitamab ITP Extension Study: Long-Term Data That Matters for Investors
11d ago
TAK
Takeda Advances Zasocitinib Trial in Vitiligo, Signaling Quiet but Important Pipeline Momentum
PremiumCompany Announcements
Takeda Advances Zasocitinib Trial in Vitiligo, Signaling Quiet but Important Pipeline Momentum
11d ago
TAK
Takeda Advances Zasocitinib Trial in Painful Skin Disease, Sharpening Its Immunology Pipeline
PremiumCompany AnnouncementsTakeda Advances Zasocitinib Trial in Painful Skin Disease, Sharpening Its Immunology Pipeline
11d ago
TAK
Takeda Earnings Call: R&D Wins Amid Revenue Pressure
Premium
Company Announcements
Takeda Earnings Call: R&D Wins Amid Revenue Pressure
12d ago
TAK
Takeda Advances TAK-279 in Ulcerative Colitis: What Investors Should Watch Next
Premium
Company Announcements
Takeda Advances TAK-279 in Ulcerative Colitis: What Investors Should Watch Next
16d ago
TAK
Takeda’s TAK-781 Trial Moves Forward in Rare Liver Disease, Quietly Building Long-Term Pipeline Value
PremiumCompany Announcements
Takeda’s TAK-781 Trial Moves Forward in Rare Liver Disease, Quietly Building Long-Term Pipeline Value
16d ago
TAK
Takeda’s Zasocitinib Trial in Psoriatic Arthritis Moves Forward, Raising New Pipeline Upside
PremiumCompany Announcements
Takeda’s Zasocitinib Trial in Psoriatic Arthritis Moves Forward, Raising New Pipeline Upside
17d ago
TAK
Takeda Deepens Real-World Safety Data for Adzynma in Ultra-Rare cTTP Market
PremiumCompany Announcements
Takeda Deepens Real-World Safety Data for Adzynma in Ultra-Rare cTTP Market
17d ago
TAK
Takeda raises FY25 core EPS view to 486 yen from 479 yen
PremiumThe Fly
Takeda raises FY25 core EPS view to 486 yen from 479 yen
17d ago
TAK
Takeda reports Q3 core EPS 428 yen vs. 443 yen last year
PremiumThe FlyTakeda reports Q3 core EPS 428 yen vs. 443 yen last year
17d ago
TAK
Takeda Advances Zasocitinib Phase 3 Trial in Psoriatic Arthritis: What Investors Should Know
Premium
Company Announcements
Takeda Advances Zasocitinib Phase 3 Trial in Psoriatic Arthritis: What Investors Should Know
18d ago
TAK
Takeda’s Phase 3 Mezagitamab Trial in ITP Moves Forward, Keeping Pipeline Hopes in Focus
Premium
Company Announcements
Takeda’s Phase 3 Mezagitamab Trial in ITP Moves Forward, Keeping Pipeline Hopes in Focus
18d ago
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >